UPDATE: Roth Capital On Corvus Pharmaceuticals: Firm Sees Termination Of Phase 3 Trial Of anti-CD73 Antibody Mupadolimab In Hypoxic Covid-19 Patients As 'Most Prudent Decision Co. Could Make' To Preserve Capital And Focus On Core Oncology Programs